NCT06851325Completed
Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes
Antiplatelets and Hemorrhagic MI
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
The MIRON-PLATELET study is a retrospective, observational multi-center analysis assessing the impact of different antiplatelet therapies on hemorrhagic myocardial infarction (HMI) incidence and outcomes in STEMI patients. Key endpoints include hemorrhagic transformation, MACE, bleeding complications, and 30-day mortality. Findings will offer insights into the safety and clinical implications of antiplatelet therapy in high-risk patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 6180 (actual)
- First submitted
- 24 Feb 2025
- Start date
- 1 May 2023
- Primary completion date
- 30 Jan 2025
- Lead sponsor
- Rohan Dharmakumar
- Diseases
- Coronary artery disease
- NCT number
- NCT06851325
What you commit to
- Study type: Observational
- Participants enrolled: 6180
- From 1 May 2023 to the primary completion date, 30 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior hemorrhagic stroke or active intracranial bleeding before the index STEMI event
- Use of chronic antiplatelet therapy (aspirin, clopidogrel, ticagrelor, prasugrel) before STEMI diagnosis
- Use of long-term anticoagulation therapy (warfarin, DOACs such as apixaban, rivaroxaban, dabigatran) before STEMI diagnosis
Other illness
- Diagnosis of non-STEMI (NSTEMI), unstable angina, or other non-ischemic cardiomyopathies
- Known bleeding disorders (e.g., hemophilia, thrombocytopenia \<50,000/µL)
- History of malignancy with life expectancy \<1 year at the time of STEMI diagnosis
Other
- Incomplete or missing medical records preventing outcome assessment
- Patients lost to follow-up before 30 days post-STEMI
Who the study is looking for
- Age ≥18-79 years at the time of STEMI diagnosis
- Diagnosed with ST-segment elevation myocardial infarction (STEMI) based on standard clinical criteria
- Received antiplatelet therapy as part of STEMI management
- Underwent primary percutaneous coronary intervention (PCI)
- Evidence of hemorrhagic MI confirmed by Cardiac Magnetic Resonance Imaging OR Post-PCI biomarker diagnostics
- Availability of comprehensive medical records documenting STEMI presentation, treatment details, and clinical outcomes
- Minimum of 30-day follow-up data, with extended follow-up available for up to 10 years
Age in the registry: 18 years to 79 years · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical Imaging Research Institute Coordinator of this site? Confirm its status | Indianapolis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.